Early vasopressor administration in pediatric blunt liver and spleen injury: An ATOMAC+ study

David M Notrica1, Bethany L Sussman1, Lois W Sayrs1

  • 1Phoenix Children's Hospital.

Insights

Early vasopressor use in pediatric blunt liver or spleen injury (BLSI) patients with hypotension increases mortality risk. However, it does not impact nonoperative management failure rates.

Area of Science:

  • Pediatric trauma surgery
  • Emergency medicine
  • Critical care

Background:

  • Limited research exists on early vasopressor use in pediatric blunt liver or spleen injury (BLSI).
  • Understanding vasopressor impact is crucial for managing pediatric trauma patients.

Purpose of the Study:

  • To investigate the outcomes of early vasopressor administration in children with BLSI.
  • To determine the association between vasopressor use and mortality and nonoperative management (NOM) failure.

Main Methods:

  • Secondary analysis of a prospective, 10-center study involving 1004 children with BLSI.
  • Used inverse probability of treatment weighting (IPTW) to compare vasopressor users (<48h) with controls.
  • Logistic regression assessed survival and NOM failure related to vasopressor initiation.

Main Results:

  • Hypotension treated with vasopressors was linked to a sevenfold increase in mortality (AOR=7.6).
  • Excluding cardiac arrest cases, mortality risk rose to an 11-fold increase (AOR=11.4).
  • All vasopressor-related deaths occurred within 12 hours of injury; no association with NOM failure was found.

Conclusions:

  • Early vasopressor use for hypotension in pediatric BLSI patients is associated with increased mortality.
  • Vasopressor administration did not elevate the risk of nonoperative management failure.
Abstract